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candidate BM212 was reported to be active against Mtb with an
MIC of 1.5 mg/mL.BM212 belongs to the MmpL3 class of inhibitors
which stops the transport of mycolic acids.
Methods & Materials: The structural similarity between an
MmpL3 inhibitor BM212 and a cannabinoid receptor modulator
rimonabant prompted us to investigate the anti-tubercular activity
of rimonabant and its analogues. Accordingly several compounds
were synthesized and their activity was evaluated against Mtb.
Results: Further optimization, particularly through incorpo-
ration of silicon into the scaffold resulted in new compounds
with signiﬁcant improvement in anti-tubercular activity against
Mycobacterium tuberculosis (H37Rv).
Repurposing of rimonabant
Conclusion: A sila analogue turned out to be the most potent
antimycobacterial compound (MIC, 31 ng/mL) from this serieswith
an excellent selectivity index. Optimization of the series to improve
its ADME properties is currently in progress.
http://dx.doi.org/10.1016/j.ijid.2016.02.870
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Background: Mycobacterium tuberculosis infection of the eye is
common in India, but the orbital infection is extremely rare. Orbital
tuberculosis occurs as a result of hematogenous spread or direct
extension from the neighboring structures. In this study we have
reviewed the clinical and microbiology features of orbital tubercu-
losis.
Methods & Materials: Medical and Microbiology records of
patients with orbital tuberculosis positive for M.tuberculosis in cul-
ture between June 2010 and May 2015 reviewed. The study data
included demographic details of the patients, clinical presentation,
interventions and reports of other investigations performed. Inci-
sion biopsy/Pus aspirate/FNAC specimen obtained from patients
were subjected to direct microscopy by Ziehl Neelsen staining,
inoculated on to Lowenstein Jensen(LJ) medium and histopathol-
ogy.
Results:A total of 6patientswithorbital tuberculosiswere iden-
tiﬁedduring the studyperiod. Fourof sixpatientswere females. The
age ranges of the patients from 7 years to 29 years. Four patients
were less than 15 years, two patients were within 15 to 30 years.
All the patients were immunocompetent. Two patients presented
with lacrimal gland mass with proptosis, one patient with chronic
orbital cellulitis, one patient with orbital cellulitis and tuberculosis
osteomyelitis, one with upper lid mass with choroidal granuloma
and one patient with upper lid mass. Mantoux test was performed
in 4/6 patients and positive in all the four patients. Chest Xwas per-
formed in 5/6 patients and no abnormality was noted in all these
patients.ESRwaselevated in3/5patients.Histopathologydiagnosis
was available for 5 patients and 4/5 patients showed granuloma-
tous inﬂammation with caseous necrosis , one with tuberculosis
osteomyelitis. Direct smear was positive for acid fast bacilli and
culture grew Mycobacterium tuberculosis on LJ medium in all the
patients. All the patients were started on anti tuberculosis treat-
ment.
Conclusion: Orbital tuberculosis should be considered as a
differential diagnosis in immunocompetent patients with orbital
swelling and abscess in TB endemic countries. In majority of
patients orbital tuberculosis occurswithout systemic involvement.
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Background: Despite the availability of highly efﬁcacious treat-
ment for decades, tuberculosis (TB) remains a major global health
problem. The widespread transmission of resistant variants of
Mycobacterium tuberculosis, which does not respond to any of the
commercial drugs, threatens health security of both developed
and developing world. The urgent need of new antimycobacterial
agents and development pathways is becoming more and more
apparent.
Methods & Materials: More than 200 new diverse struc-
tures, including more than 50 new synthetic chiral compounds
derived from natural terpenoids (+)-camphor and (-)-fenchone
were synthesized. The compounds were evaluated for their in vitro
antimycobacterial activity by proportional method against ref-
erence strain Mycobacterium tuberculosis H37Rv and multidrug
resistant Mycobacterium tuberculosis strain 43.
Results: Thequantitative structure–activity relationship (QSAR)
revealed several structural requirements: two hydrogen bond
donors, two or three rings and no large branched substituents. We
describe the design of a set of nine novel camphane-based deriva-
tives following these requirements. Four of them showed activities
in the nanomolar range, signiﬁcantly higher than the activities in
the initial set. Many structures showed promising antimycobacte-
rial activity (MIC up to 0.27M) – 10 to 20 fold higher than activity
of ethambutol in combination with insigniﬁcant cytotoxicity (IC50
more than 354 M toward human embryonal kidney cell line).
